Insider Trading Alert - Fiserv And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 10, 2013, 135 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $49.60 to $313,828,000.00.

Highlighted Stocks Traded by Insiders:

Fiserv (FISV) - FREE Research Report

Yabuki Jeffery W who is President & CEO at Fiserv sold 4,000 shares at $98.88 on Sept. 10, 2013. Following this transaction, the President & CEO owned 151,828 shares meaning that the stake was reduced by 2.57% with the 4,000 share transaction.

The shares most recently traded at $100.86, up $1.98, or 1.96% since the insider transaction. Historical insider transactions for Fiserv go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 9,500
  • 24-Week # shares sold: 26,829

The average volume for Fiserv has been 574,500 shares per day over the past 30 days. Fiserv has a market cap of $12.9 billion and is part of the services sector and diversified services industry. Shares are up 25.93% year to date as of the close of trading on Tuesday.

Fiserv, Inc., together with its subsidiaries, provides financial services technology worldwide. The company has a P/E ratio of 23.5. Currently there are 8 analysts that rate Fiserv a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FISV - FREE

TheStreet Quant Ratings rates Fiserv as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Fiserv Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Microsoft Corporation (MSFT) - FREE Research Report

Gates William H Iii who is Director at Microsoft Corporation sold 10.0 million shares at $31.38 on Sept. 10, 2013. Following this transaction, the Director owned 378.0 million shares meaning that the stake was reduced by 2.58% with the 10.0 million share transaction.

The shares most recently traded at $32.72, up $1.34, or 4.09% since the insider transaction. Historical insider transactions for Microsoft Corporation go as follows:

  • 4-Week # shares sold: 10.2 million
  • 12-Week # shares sold: 10.2 million
  • 24-Week # shares sold: 17.6 million

The average volume for Microsoft Corporation has been 53.4 million shares per day over the past 30 days. Microsoft Corporation has a market cap of $263.7 billion and is part of the technology sector and computer software & services industry. Shares are up 18.52% year to date as of the close of trading on Tuesday.

Microsoft Corporation (Microsoft) develops, licenses, and supports software, services, and hardware devices worldwide. The stock currently has a dividend yield of 2.91%. The company has a P/E ratio of 12.3. Currently there are 10 analysts that rate Microsoft Corporation a buy, no analysts rate it a sell, and 17 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSFT - FREE

TheStreet Quant Ratings rates Microsoft Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Microsoft Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

UGI Corporation (UGI) - FREE Research Report

Oliver Kirk R who is Cfo at UGI Corporation bought 5,000 shares at $38.48 on Sept. 10, 2013. Following this transaction, the Cfo owned 5,000 shares meaning that the stake was reduced by 100% with the 5,000 share transaction.

The shares most recently traded at $38.64, up $0.16, or 0.41% since the insider transaction. Historical insider transactions for UGI Corporation go as follows:

  • 4-Week # shares bought: 1,800
  • 4-Week # shares sold: 18,343
  • 12-Week # shares bought: 1,800
  • 12-Week # shares sold: 18,343
  • 24-Week # shares bought: 1,800
  • 24-Week # shares sold: 18,343

The average volume for UGI Corporation has been 536,200 shares per day over the past 30 days. UGI Corporation has a market cap of $4.4 billion and is part of the utilities sector and utilities industry. Shares are up 18.77% year to date as of the close of trading on Tuesday.

Natural Gas Utility, (NYSE: UGI), distributor and marketer of energy products and services. The stock currently has a dividend yield of 2.95%. The company has a P/E ratio of 16.1. Currently there is 1 analyst that rates UGI Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UGI - FREE

TheStreet Quant Ratings rates UGI Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, reasonable valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full UGI Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

PetSmart (PETM) - FREE Research Report

Perricone Jaye D who is SVP Real Estate & Development at PetSmart sold 8,359 shares at $71.75 on Sept. 10, 2013. Following this transaction, the SVP Real Estate & Development owned 1,180 shares meaning that the stake was reduced by 87.63% with the 8,359 share transaction.

The shares most recently traded at $72.16, up $0.41, or 0.57% since the insider transaction. Historical insider transactions for PetSmart go as follows:

  • 12-Week # shares sold: 10,010
  • 24-Week # shares sold: 40,617

The average volume for PetSmart has been 1.1 million shares per day over the past 30 days. PetSmart has a market cap of $7.3 billion and is part of the services sector and specialty retail industry. Shares are up 4.93% year to date as of the close of trading on Tuesday.

PetSmart, Inc., together with its subsidiaries, operates as a specialty retailer of products, services, and solutions for pets in the United States, Puerto Rico, and Canada. The stock currently has a dividend yield of 0.93%. The company has a P/E ratio of 18.4. Currently there are 5 analysts that rate PetSmart a buy, no analysts rate it a sell, and 14 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETM - FREE

TheStreet Quant Ratings rates PetSmart as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, revenue growth, notable return on equity, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full PetSmart Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Ariad Pharmaceuticals (ARIA) - FREE Research Report

Clackson Timothy P who is President, R&D, CSO at Ariad Pharmaceuticals sold 8,449 shares at $22.00 on Sept. 10, 2013. Following this transaction, the President, R&D, CSO owned 370,451 shares meaning that the stake was reduced by 2.23% with the 8,449 share transaction.

The shares most recently traded at $22.35, up $0.35, or 1.57% since the insider transaction. Historical insider transactions for Ariad Pharmaceuticals go as follows:

  • 4-Week # shares sold: 112,902
  • 12-Week # shares sold: 369,902
  • 24-Week # shares sold: 557,000

The average volume for Ariad Pharmaceuticals has been 2.4 million shares per day over the past 30 days. Ariad Pharmaceuticals has a market cap of $4.0 billion and is part of the health care sector and drugs industry. Shares are up 17.41% year to date as of the close of trading on Tuesday.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Currently there are 12 analysts that rate Ariad Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARIA - FREE

TheStreet Quant Ratings rates Ariad Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Ariad Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

A Few Trade Ideas Ahead of Dow 20,000

A Few Trade Ideas Ahead of Dow 20,000

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Analysts' Actions -- Quintiles, Royal Caribbean, Western Digital and More

Analysts' Actions -- Quintiles, Royal Caribbean, Western Digital and More

'Mad Money' Lightning Round: Don't Sell Scripps

'Mad Money' Lightning Round: Don't Sell Scripps